Pharmacogenetics and healthcare outcomes in patients with chronic heart failure

European Journal of Clinical Pharmacology

Volumn 68, Issue 11, 2012, Pages 1483-1491

  Kim, Kye Min ^a,b   Murray, Michael D ^c,d   Tu, Wanzhu ^d,e   Robarge, Jason ^b   Ding, Yan ^b   Brater, D Craig ^b   Flockhart, David A ^b,f  

^a Inje University College of Medicine   (South Korea)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PURDUE UNIVERSITY   (United States)

^d REGENSTRIEF INSTITUTE   (United States)

^e INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^f INDIANA UNIVERSITY   (United States)

Author keywords

Health outcomes; Heart failure; Pharmacogenetics; Treatment adherence

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 4A11; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTAMINE; GLYCINE; LOOP DIURETIC AGENT; SPIRONOLACTONE; THREONINE;

ACE GENE; ADRA2C GENE; ADRB1 GENE; ADRB2 GENE; ADULT; ARTICLE; CONTROLLED STUDY; CYP4A11 GENE; DEMOGRAPHY; ENOS GENE; FEMALE; FUNCTIONAL STATUS; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEALTH CARE UTILIZATION; HEART FAILURE; HETEROZYGOTE; HOMOZYGOSITY; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AMINO ACID SUBSTITUTION; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HEART FAILURE; HETEROZYGOTE; HOSPITALIZATION; HUMANS; INDIANA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SINGLE-BLIND METHOD;

EID: 84867574617     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1280-z     Document Type: Article

References (33)

1. Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA 273(18):1450-1456
2. Foody JM, Farrell MH, Krumholz HM (2002) Beta-blocker therapy in heart failure: scientific review. JAMA 287(7):883-889 (Pubitemid 34252037)
3. Drexler H (1999) Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation 99(23):2972-2975 (Pubitemid 29270423)
4. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347(15):1135-1142
5. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86(4):1343-1346 (Pubitemid 20370444)
6. McNamara DM, Holubkov R, Postava L, Ramani R, Janosko K, Mathier M, MacGowan GA, Murali S, Feldman AM, London B (2003) Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 107(12):1598-1602 (Pubitemid 36397327)
7. Tu W, Morris AB, Li J, Wu J, Young J, Brater DC, Murray MD (2005) Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther 77(3):189-201 (Pubitemid 40269134)
8. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D (1993) Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88(1):107-115 (Pubitemid 23195439)
9. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV (2003) Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290(19):2581-2587 (Pubitemid 37443288)
10. Majahalme SK, Baruch L, Aknay N, Goedel-Meinen L, Hofmann M, Hester A, Prescott MF, Feliciano N (2005) Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial). Am J Cardiol 95(4):529-532 (Pubitemid 40247557)
11. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB (2000) A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 275(30):23059-23064 (Pubitemid 30646196)
12. Rathz DA, Brown KM, Kramer LA, Liggett SB (2002) Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39(2):155-160 (Pubitemid 34093534)
13. Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274(18):12670-12674 (Pubitemid 29215505)
14. Green SA, Turki J, Innis M, Liggett SB (1994) Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33(32):9414-9419 (Pubitemid 24272896)
15. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P (2002) The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 20(10):2023-2027 (Pubitemid 35305500)
16. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S, Hopper RV, Stephens NG, O'Shaughnessy KM, Brown MJ (1999) A common variant of the endothelial nitric oxide synthase (Glu298->Asp) is a major risk factor for coronary artery disease in the UK. Circulation 100(14):1515-1520 (Pubitemid 29461463)
17. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F (1992) Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51(1):197-205
18. Danser AH, Derkx FH, Hense HW, Jeunemaitre X, Riegger GA, Schunkert H (1998) Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 16(12 Pt 2):1879-1883 (Pubitemid 29002363)
19. Andersson B, Sylven C (1996) The DD genotype of the angiotensin- converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 28(1):162-167 (Pubitemid 26266636)
20. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo C-Y, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH (2005) Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111(1):63-69. doi: 10.1161/01.cir.0000151309.82473.59 (Pubitemid 40070845)
21. Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, Stroupe KT, Wu J, Clark D, Smith F, Gradus-Pizlo I, Weinberger M, Brater DC (2007) Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med 146(10):714-725 (Pubitemid 351639999)
22. Small KM, Rathz DA, Liggett SB (2002) Identification of adrenergic receptor polymorphisms. Methods Enzymol 343:459-475 (Pubitemid 32954159)
23. Tanus-Santos JE, Desai M, Flockhart DA (2001) Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11(8):719-725 (Pubitemid 33078242)
24. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH (1995) A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 332(11):706-711
25. Shanmugam V, Sell KW, Saha BK (1993) Mistyping ACE heterozygotes. PCR Methods Appl 3(2):120-121
26. Westfall PH, Tobias R, Rom D, Wolfinger RD, Hochberg Y (1999) Multiple comparisons and multiple tests using the SAS system. SAS Institute, Cary
27. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto Y, Nakao K (1998) A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103(1):65-69 (Pubitemid 28398388)
28. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hill JA, Aranda JM, Yarandi HN, Johnson JA (2005) Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 15(4):227-234 (Pubitemid 40569894)
29. de Groote P, Helbecque N, Lamblin N, Hermant X, McFadden E, Foucher-Hossein C, Amouyel P, Dallongeville J, Bauters C (2005) Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 15(3):137-142 (Pubitemid 40569899)
30. de Groote P, Lamblin N, Helbecque N, Mouquet F, Mc Fadden E, Hermant X, Amouyel P, Dallongeville J, Bauters C (2005) The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail 7(6):966-973 (Pubitemid 41443589)
31. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR (2006) A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103(30):11288-11293 (Pubitemid 44156511)
32. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA (2005) Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 294(12):1526-1533 (Pubitemid 41362690)
33. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J (1994) Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 154(4):433-437 (Pubitemid 24072217)